Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson J P
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
J Biol Chem. 1994 May 6;269(18):13273-8.
The complement receptor type 1 (CR1; CD35), carrying 30 short consensus repeats (SCRs), has two sites. Site 1 contains SCR-1 and SCR-2 and binds C4b. Site 2 contains SCR-8 and SCR-9 and was reported to bind mainly C3b (Klickstein, L. B., Bartow, T. J., Miletic, V., Rabson, L. D., Smith, J. A., and Fearon, D. T. (1988) J. Exp. Med. 168, 1699-1717). For the functional analysis we used two constructs, each with one site. CR1-4, composed of eight and one-half initial SCRs, carries site 1, binds C4b, and is cofactor for C4b cleavage. CR1-4(8,9), obtained from CR1-4 by converting site 1 to site 2, binds iC3/C3b and, unexpectedly, C4b. It is a cofactor for cleavage of both ligands. Its cofactor activity for C4b cleavage is greater than that of site 1. Analysis of the mutants constructed by interchanging homologous peptides between the two sites identified no sequences necessary for cofactor activity other than those required for binding. In site 2, peptides important for both ligands were found. Some modifications of either site led to higher activity for both ligands. Thus the activity of complement regulators can be increased by changing a few amino acids within SCRs, an important step toward the generation of more effective inhibitors of complement activation. Knowledge of the active sites of CR1 should be applicable to other SCR-containing proteins and should provide insights into the evolution of these proteins.
1型补体受体(CR1;CD35)带有30个短共有重复序列(SCR),有两个位点。位点1包含SCR - 1和SCR - 2,可结合C4b。位点2包含SCR - 8和SCR - 9,据报道主要结合C3b(Klickstein,L.B.,Bartow,T.J.,Miletic,V.,Rabson,L.D.,Smith,J.A.,和Fearon,D.T.(1988年)《实验医学杂志》168,1699 - 1717)。为进行功能分析,我们使用了两种构建体,每种构建体有一个位点。CR1 - 4由八个半起始SCR组成,携带位点1,结合C4b,是C4b裂解的辅助因子。CR1 - 4(8,9)是通过将位点1转换为位点2从CR1 - 4获得的,结合iC3/C3b,且出乎意料地还结合C4b。它是两种配体裂解的辅助因子。其对C4b裂解的辅助因子活性大于位点1。对通过在两个位点之间互换同源肽构建的突变体进行分析发现,除了结合所需的序列外,没有其他辅助因子活性必需的序列。在位点2中,发现了对两种配体都重要的肽段。对任何一个位点的一些修饰都会导致对两种配体都有更高的活性。因此,通过改变SCR内的几个氨基酸可以提高补体调节蛋白的活性,这是朝着生成更有效的补体激活抑制剂迈出的重要一步。了解CR1的活性位点应适用于其他含SCR的蛋白质,并应为这些蛋白质的进化提供见解。